Abstract:Background: Obesity is common among older adults in the US, but Medicare policies prohibit coverage of anti-obesity medications (AOMs) and may limit access to effective treatment. Objective: To describe first-time prescribing and dispensing of AOM glucagon-like peptide-1 receptor agonists (GLP-1 RA) among eligible older adults, stratified by Medicare age eligibility. Methods: Adults aged 60-69 with overweight or obesity and without Type II diabetes (T2D) were identified from Truveta Data. Data included EHR (encounters, prescriptions, conditions, BMI) and medication dispensing for a collective of US healthcare systems. Eligibility required an outpatient office encounter between June 2021 and January 2024 with a BMI of 27 or higher, a negative history of GLP-1 RA use, and a follow-up at least 60 days later. Patients were stratified by Medicare age eligibility (60-64 vs. 65-69) and the proportions prescribed and subsequently dispensed AOM GLP-1 were compared. Results: In total, 413,833 AOM eligible older adults were included in our cohort, with 208,067 (50.3%) Medicare-aged adults and 205,766 (49.7%) adults aged 60-64. Among eligible patients, 0.2% of Medicare-aged patients and 0.4% of patients aged 60-64 were prescribed AOM GLP-1 RA, a significant difference (p < 0.01). Among those prescribed AOM GLP-1 RA, 15.2% of Medicare-aged patients and 22.7% of patients aged 60-64 were dispensed AOM GLP-1 RA within 60 days, a significant difference (p<0.01). In both age groups, prescribing and dispensing were relatively more common for females and those with higher BMI. Conclusions: Fewer than 1% of older adults with overweight or obesity and without T2D were prescribed an AOM GLP-1 RA. New use of GLP-1 RA was significantly lower for Medicare-aged adults, compared to 60-64-year-olds, with differences occurring at both medication prescribing and dispensing stages. While coverage of AOMs is limited by many insurers, Medicare's unique prohibition on AOM coverage may contribute to differentially lower use among Medicare-aged adults.

Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable

Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By $3.1 Billion To $6.1 Billion

US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity

Net prices of new antiobesity medications

Estimating the lives that could be saved by expanded access to weight-loss drugs

Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists

Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists

Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications

Heightened Vigilance Needed When Patients Are Prescribed GLP-1 and GIP Agonists

GLP-1 Agonists for Obesity—A New Recipe for Success?

Access to Anti-Obesity GLP-1s for Medicare-Aged Adults

Public health perspective on new weight loss medications

Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity

Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care

Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management

GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications

Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss

Effectiveness and safety of drugs for obesity

Treating Obesity and Fertility in the Era of Glucagon-like Peptide 1 Receptor Agonists

Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity

The cost‐effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity